Key result
Out-of-office monitoring reveals masked hypertension in ~23% of nondialysis CKD patients, alongside frequent nocturnal abnormalities.
Why the study?
The prevalence of masked hypertension, white-coat hypertension, nondipping, and nocturnal hypertension phenotypes in nondialysis CKD patients remains unclear, complicating diagnosis and treatment.
Meta-Analysis (n=41,989)
Yes
Nondialysis CKD patients have a substantial burden of masked, nocturnal, and nondipping hypertension, strongly supporting the routine use of out-of-office blood pressure monitoring in this population.
Substantial masked, nocturnal, and nondipping hypertension burden in nondialysis CKD supports out-of-office monitoring; leaves open outcome benefits in prospective trials.
In nondialysis chronic kidney disease (CKD) patients, masked hypertension (MH), white-coat hypertension (WCH), nondipping, and nocturnal hypertension phenotypes are known to complicate the diagnostic and therapeutic approach, but their prevalence remains unclear. A systematic search of two databases (PubMed, EmBase) from inception through October 1, 2025 was performed to identify records reporting MH, WCH, nocturnal hypertension, and nondipping prevalence in this population. A meta-analysis (REML model) was conducted to calculate respective pooled prevalences. From 2355 records screened, 68 were selected including 41 989 patients. Meta-analysis of 33 studies (n = 26 539, weighted mean age 60.9 years, 58% males, mean eGFR 49.3 ml/min) indicated 11% pooled WCH prevalence [95% confidence interval (CI) (8, 14%)]. Further analyses (33 studies, n = 26 542) indicated pooled MH prevalence 23% (19, 27%), pooled nondipping and dipping prevalence 66% (61, 70%) and 34% (30, 39%), respectively (49 studies, n = 22 773 - two phenotype analysis) and pooled dipping, nondipping, extreme dipping and reverse dipping pooled prevalence 28% (24, 33%), 43% (40, 46%), 3% (2, 6%), 23% (18, 27%) respectively (20 studies, n = 10 865 - four phenotype analysis). Meta-analysis of 14 studies (n = 15 701) indicated nocturnal hypertension prevalence 57% (47, 67%). Ambulatory and home blood pressure monitoring were equivalent in detecting WCH and MH (P = 0.68/0.4, respectively). Glomerular filtration rate was not associated with the MH/WCH prevalence. Nondialysis CKD patients experience an important burden of MH, nocturnal hypertension and nondipping, and lesser WCH. These results strongly support the necessity for out-of-office blood pressure evaluation in these patients.
No takes yet. Share an insight, caveat, or question.
Thymis et al. (2026) conducted a meta-analysis in Nondialysis chronic kidney disease (CKD) (n=41,989). Hypertension phenotypes (masked, white-coat, nondipping, nocturnal) was evaluated on Prevalence of hypertension phenotypes. In nondialysis chronic kidney disease patients, the pooled prevalence of masked hypertension was 23%, nondipping was 66%, and nocturnal hypertension was 57%, with lesser white-coat hypertension (11%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: